Laurent Humeau | Chief Scientific Officer, Evp Of Research, Engineering And Clinical Developments
Inovio Pharmaceuticals

Laurent Humeau, Chief Scientific Officer, Evp Of Research, Engineering And Clinical Developments, Inovio Pharmaceuticals

As Chief Scientific Officer, Dr. Humeau works to ensure continuous and strategic growth of Inovio’s pipeline by introducing a constant flow of innovative concepts and cycling them from early stage discovery and development through clinical application and patient monitoring. He provides technical and strategic leadership across multiple teams that are essential to upstream and downstream verticals of clinical development. Dr. Humeau leads with a collaborative spirit and deeply believes in the company’s core values. He is a valuable member of the leadership team who greatly contributes to Inovio’s culture. Prior to Inovio, Dr. Humeau was Senior Director of Translational Research, Human Therapeutics Division for Intrexon and previously Chief Scientific Officer, Vice President of R&D at VIRxSYS Corporation. Dr. Humeau holds a Ph.D., summa cum laude, from Denis Diderot/Paris 7 University and a MS degree from Pierre & Marie Curie/Paris 6 University, Paris, France.

Appearances:



Day 3, April 9 @ 12:00

Late stage development of a novel DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus (HPV)

last published: 17/Feb/20 09:15 GMT
last published: 17/Feb/20 09:15 GMT
last published: 17/Feb/20 09:15 GMT
last published: 17/Feb/20 09:15 GMT
last published: 17/Feb/20 09:15 GMT
last published: 17/Feb/20 09:15 GMT
last published: 17/Feb/20 09:15 GMT
last published: 17/Feb/20 09:15 GMT
last published: 17/Feb/20 09:15 GMT
last published: 17/Feb/20 09:15 GMT
last published: 17/Feb/20 09:15 GMT

back to speakers